FilingReader Intelligence
Haisco Pharmaceutical Group restructures control, advances novel drug
March 31, 2025 at 07:48 AM UTC•By FilingReader AI
Haisco Pharmaceutical Group (SZSE:002653) announced a significant shift in its corporate control structure. Shareholders Wang Junmin, Fan Xiulian, and Zheng Wei have terminated their concerted action agreement. The primary effect of this is that Wang Junmin will become the sole controlling shareholder, replacing the previous collective control.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Announcement on Obtaining the "Drug Clinical Trial Approval Notice" for the Innovative Drug HSK41959 TabletsMarch 26, 2025 at 08:15 AM UTC
Legal opinion of Zhong Lun (Shenzhen) Law Firm of Beijing on the termination of the concerted action agreement by relevant shareholders of Hiseco Pharmaceutical Group Co., Ltd. and the change of controlling shareholder and actual controllerMarch 30, 2025 at 07:35 AM UTC
SZSE:002653•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Haisco Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime